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Abstract
Schistosomiasis is a serious disease currently estimated to affect more that 207 million peo-
ple worldwide. Due to the intensive use of praziquantel, there is increasing concern about
the development of drug-resistant strains. Therefore, it is necessary to search for and inves-
tigate new potential schistosomicidal compounds. This work reports the in vivo effect of the
alkaloid epiisopiloturine (EPI) against adults and juvenile worms of Schistosoma mansoni.
EPI was first purified its thermal behavior and theoretical solubility parameters charaterised.
In the experiment, mice were treated with EPI over the 21 days post-infection with the
doses of 40 and 200 mg/kg, and 45 days post-infection with single doses of 40, 100 and
300 mg/kg. The treatment with EPI at 40 mg/kg was more effective in adult worms when
compared with doses of 100 and 300 mg/kg. The treatment with 40 mg/kg in adult worms re-
duced parasite burden significantly, lead to reduction in hepatosplenomegaly, reduced the
egg burden in faeces, and decreased granuloma diameter. Scanning electron microscopy
revealed morphological changes to the parasite tegument after treatment, including the loss
of important features. Additionally, the in vivo treatment against juvenile with 40 mg/kg
showed a reduction of the total worm burden of 50.2%. Histopathological studies were
performed on liver, spleen, lung, kidney and brain and EPI was shown to have a DL50 of
8000 mg/kg. Therefore EPI shows potential to be used in schistosomiasis treatment. This is
the first time that schistosomicidal in vivo activity of EPI has been reported.
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Author Summary
Schistosomiasis, a disease caused by worms from the genus Schistosoma, is one of the most
widespread neglected tropical diseases in the world. Due to the intensive use of praziquan-
tel, some reports of drug resistance have emerged. Thus it is important to search for new
chemotherapeutic agents for the treatment disease. This research showed that epiisopilo-
turine, an imidazole alkaloid extracted from the leaves of Pilocarpus microphylus, has ac-
tivity against S.mansoni in vivo. This material is produced as a by-product of an existing
commercial process, and thus can be produced in large quantities at relatively low cost.
The low toxicity and high drug tolerance in mammals shows the potential of epiisopilotur-
ine as a new candidate schistosomicidal compound.
Introduction
Schistosomiasis is a disease mainly found in tropical regions, whose infectious agents are Schis-
tosoma spp., including Schistosoma mansoni [1]. This disease is currently one of the most wide-
ly occurring neglected tropical diseases with high levels of incidence in Asia, Africa and Latin
America. Studies have shown that more than 207 million people have been infected worldwide
and about 779 million people are liable to infection [2].
Currently praziquantel (PZQ) is effective against all specie of Schistosoma. Presenting good
efficacy and low toxicity, it is currently the reference drug for schistosomiasis treatment [3–6].
However, as PZQ is the only drug used in therapy against schistosomiasis, concern about the
development of drug resistance has been reported [7,8].
The search for new antischistosomal drugs has led to the study of natural substances such as
artemisinin and its derivatives (e.g. artemether, artenusate), curcumin, phytol and epiisopilo-
turine (EPI) has been intensified [9–14]. We have been specifically interested in EPI which is
an imidazole alkaloid extracted from Pilocarpus microphyllus, whose in vitro activity against
S.mansoni at the concentration of 150 μg/mL led to the observation of dead parasites, and at
the sub-lethal dose, prevented egg laying [14]. Moreover, this alkaloid showed potent anti-
inflammatory activity [15], which might help combat the granuloma and inflammatory reac-
tion caused by S.mansoni eggs.
Despite this promising evidence of in vitro activity, nothing has been reported until now
about in vivo antischistosomal activity of EPI. In this paper, we describe the in vivo schistoso-
micidal activity of EPI against adult and juvenile S.mansoni worms for the first time. We also
show scanning electron microscopy data revealing action of the alkaloid on the parasite tegu-
ment. Furthermore, the effects of the alkaloid in egg laying, reduction of hepatosplenomegaly,
histopathology analysis and analysis of granulomas, in treated mice, are also characterised.
Materials and Methods
Purification and Characterization of EPI
This step was based on Véras et al., 2013 [16] by preparative high performance liquid chroma-
tography—HPLC (SHIMADZU Prominence, SIL-10AF, CTO-20A, DGU-20A5, LC-6AD,
CBM-20A, SPD-20A, Tokyo, Japan), and the molecular mass confirmation was performed by
spectrometry (AmaZon SL, Bruker Daltonics, Bremen, Germany).
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Potentiometric pKa determination
The acidity constant of EPI was potentiometrically determined in MeOH:H2O (1:1, v:v) at
t = 25±1°C and at constant ionic strength (I = 0.1 M (NaCl)). Solutions of NaOH (0.1 M) and
HCl (0.1 M) were prepared in MeOH:H2O (1:1, v:v) and potentiometrically standardized. EPI
was dissolved in methanol and diluted with the equivalent volume of aqueous 0.2 M NaCl
(cEPI = 9.7789×10
-4 M). Titrations were performed using CRISON pH-Burette 24 2S equipped
with CRISON 50 29 micro-combined pH electrode (CRISON INSTRUMENTS, S.A. Spain).
The electrode was calibrated by means of a strong acid—strong base titration, using GLEE—
glass electrode evaluation software [17]; standard potential E0 = 395.7 mV, slope factor of the
electrode (actual slope divided by ideal Nernstian slope) sf = 1.010, and pKW 13.84±0.01 ob-
tained as mean values of four titrations.
Prior to titration, 100.0 μL of the standard 0.1 M HCl solution was added to 4.00 mL of the
EPI solution. All probes were titrated with 2.0 μL increments of the standard 0.1 M NaOH so-
lution in 2.9–11.2 pH range. HyperQuad 2008 software [18] was used to calculate the value of
acidity constant (pKa) from four repeated titrations.
A theoretical pKa study was performed. The ChemAxon method [19,20], implemented in
the MarvinSketch package (Marvin 5.4.1.1, 2011, ChemAxon (http://www.chemaxon.com),
was applied. This method is based on empirically calculated physico-chemical parameters
(mainly partial charges) that are obtained from ionization site specific regression equations, it
uses three types of calculated parameters (intramolecular interactions, partial charges and po-
larizabilities) to determine the micro ionization constants pKa of monoprotic molecules. In ad-
dition, we calculated the intrinsic solubility for the compound, which is a crucial solubility
parameter. The prediction uses a fragment-based method that identifies different structural
fragments in the molecule and calculates their solubility contribution. The implementation is
based on the article of Hou et al., 2004 and it can found in ChemAxon package [21].
In addition, the thermal properties of EPI were evaluated. Differential scanning calorimetry
(DSC) and thermal gravimetric analysis (TGA) were used to determine the thermal mass loss,
as well as to study the EPI thermal decomposition to determine if it’s possible that polymorphic
forms were present. Simultaneous DSC/TGA and DSC analysis were carried out with an initial
sample mass of 5.0 mg in alumina pans (90 lL). A SDT-Q600 calorimeter, allowing simulta-
neous measurement of weight change and differential heat flow (TA Instruments) was applied
in these studies. Experimental parameters for TGA curve included the mass used of 5 mg, heat-
ing rate of 10°C min-1 under N2 flow (50 mL min
-1) and final temperature of 1000°C.
Parasites, intermediate and definitive hosts
In this study the BH strain of Schistosoma mansoni, originated from Belo Horizonte, Minas Ge-
rais, Brazil was used. The life cycle of S.mansoni was maintained in Biomphalaria glabrata
snails at the Department of Animal Biology, IB, Unicamp. As the definitive host, Balb/C mice
female, weighing ~ 20 g and 4 weeks of age, were previously infected exposure to a suspension
containing approximately 70 cercaria using the tail immersion technique as described by Oliver
and Stirewalt, 1952 [22]. The experiments were approved by the Ethics Commission for the
Use of Animals (CEUA/UNICAMP, protocol no 2170–1), as they were in accordance with the
ethical principles of animal experimentation adopted by CEUA.
In vivo treatment with the EPI
Treatment of adult worms. For in vivo treatment of adult worms, the animals were treat-
ed 45 days post-infection and single doses of 40, 100 and 300 mg/kg of EPI were used. The
dose of 40 mg/kg was selected based on previous studies describing the activity of PZQ in
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humans [23], and also because it is a commonly prescribed dosage for individuals infected with
the disease. For both treatments, the samples was solubilized in solution of phosphate buffered
saline (PBS) with 0.1% Tween-80 Polysorbate (Merck
1
). Forty-five days post infection the ani-
mals were divided into 4 main groups, with 10 animals each: infected untreated mice served as
controls (Group I) and test subjects were EPI-treated mice treated with single doses of 40, 100
and 300 mg/kg (Group II, III and IV, respectively). All animals groups were treated orally. The
group I consisted of a control group only received PBS. It is important to mention that in the
experiment with EPI 100 mg/kg three mice died.
Treatment of juvenile worms. For in vivo treatment against juvenile worms, single doses
of 40 and 300 mg/kg of EPI were used. Twenty-one days post infection the animals were divid-
ed into 3 main groups, with 8 animals each: infected untreated mice served as controls (Group
I) and EPI-treated mice with 40 and 300 mg/kg (Group II and III). Group I consisted of a
group only treated with PBS. The mice were treated orally in the same manner described in
item a.
Worm and egg burden estimation
The animals of all groups were sacrificed 15 days post-treatment, the mice were euthanized
using cervical dislocation and S.mansoni worms were retrieved by perfusion of the hepatic por-
tal system and mesenteric veins according to Pellegrino and Siqueira, 1956 [24]. The percent-
age of worm reduction (WR) was calculated according to Delgado et al., 1992 [25]. The
counting of the eggs eliminated at the faeces was performed on the day of the analysis of the
treatments. The faeces were collected before the euthanasia and were examined, utilizing the
Kato-Katz quantitative method [26]. The slides were examined for S.mansoni eggs under a
light microscope. After the perfusion portal system, a fragment of the intestine (2 cm) was cut
off and processed for oogram. Eggs were then counted and classified according to different
stages of development [27].
Scanning Electron Microscopy (SEM)
Parasites were initially fixed in AFA solution, a 2:9:30:59 mixture of acetic acid, formaldehyde,
ethanol (95%) and distilled water [28]. AFA was removed and replaced with a secondary fixa-
tive, osmium tetroxide (OsO4) in cacodylate buffer 100mM, pH 7.3. Secondary fixing took
place for 2 h with gentle shaking. OsO4 was removed and replaced with cacodylate as above—
twice. The cacodylate buffer was then replaced with ultrapure water—twice. Samples were then
air-dried from water onto adhesive carbon tape, coated with gold-palladium for conductivity,
and imaged in the SEM. The SEM was a FEI quanta 400 SEM, operating in secondary electron
mode. Samples were imaged with a working distance of 10–15 mm and an accelerating voltage
of 15kV. The back-scattered electron detector was removed from the SEM to increase the field
of view.
Hepatic histopathology and granuloma measurement
Regarding the histological analysis, liver samples (left lobe) were taken from of three mice:
treated and control group (infection untreated). The samples were processed for histopatholo-
gy following standard techniques [29], stained with hematoxylin and eosin and analysed with
the Leica
1
DM500-ICC50 HD photomicroscope. Measurements were made only for granulo-
mas containing a single egg in their centers. The mean diameter (μm) of each granuloma was
obtained by measuring two diameters of the lesions at right angles to each other with the help
of an ocular micrometer [30].
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The percentage of degenerated eggs was calculated from the number of degenerated mira-
cidia (acellular or partially or completely degenerated) using the formulation: mean number of
degenerated ova/mean number of granulomas X 100 [31].
Toxicity and histopathological studies
For the determination of lethal dose capable of killing 50% of animals (DL50), Swiss female
mice (n = 4), aged 3.5 ± 0.5 months and weighing 29.8 ± 1.3 g were used, based on Valadares
(2006) [32]. Concentrations higher than the therapeutic dose of 40 mg/kg, which was previous-
ly identified in treating animals infected with S.mansoni were used in the assay. Initially,
EPI was diluted in 10% DMSO and subsequently in 0.9% saline solution; the concentrations
(0, 70, 130, 270, 530, 1070, 2130, 4270, 8000 mg/kg) were calculated based on the average
weight of the animals and administered to animals intraperitoneally. During the assay, the ani-
mals were monitored periodically to identify visible clinical signs in the heart (abnormal heart-
beat), lung (abnormal respiratory rate) and motor system (ataxia and/or prostration).
Histopathological studies were performed on liver, spleen, lung, kidney and brain. Some ani-
mals were killed due to the administration of higher concentration, while the rest of them were
killed 7 days after the intraperitoneal injection of the drug. Hematoxilin & Eosin staining was
used with 100X magnification. [33].
Statistical analysis
Statistical tests were performed with Graphpad Prism (version 5.0) software. Dunnet’s test was
used to analyze the statistical significance of differences between mean experimental and con-
trol values and by applying Tukey’s test for multiple comparisons with the level of significance
set at P< 0.05.
Results
Characterization of EPI
The HPLC retention time and characteristic fragments generated through mass spectrometry
is in accordance with previously described data [16, 34].
In the physiological pH range, EPI acts as a base with an sp2 nitrogen in the imidazole ring
that can be protonated (Fig. 1A). According to potentiometrically determined pKa value (pKa
6.25 ± 0.05) and the distribution diagram shown on Fig. 1B, at pH 7.4, 93.5% of EPI is present
in its molecular form and 6.5% in the protonated form.
The pKa calculation for EPI presents 3 different ionic forms shown in Fig. 1B. By plotting
the theoretical titration curves, i.e. the ratio of the ionized and neutral forms versus the pH
(Fig. 1C), one can identify the ionic species which are present in the mixture at each pH value.
From this plot we identify the predicted pKa values as pKa1 = 6.4 and pKa2 = 13.9. The micro-
species distribution at pH = 7.40 was 1 = 90.55%, 2 = 9.45%and 3 = 0.0%. The solubility was
also calculated and the results show that EPI has a high apparent solubility in water at pH 7.4
(higher than 0.06 mg/mL), with intrinsic solubility equal to -1.76 logS units. An analysis of the
thermal data indicates that EPI degradation occurs in one step at a high temperature (Fig. 1D).
The single stage involves a mass decay of 91.22% (calculated: 4.051 mg; onset: 222.81°C) associ-
ated with an endothermic DTA signal (Fig. 1E). The analysis of this thermal data indicates that
EPI can be used safely, with no risk of thermally-activated degradation or alteration in
the organism.
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Effect of EPI on juvenile S.mansoni
The mice treated with the dose of 40 and 300 mg/kg of EPI, after 21 days of infection showed
significant differences (P<0.01 and P< 0.01) regarding the reduction of total worm burden.
The treatments performed against juvenile worms showed a moderate reduction of the total
worm burden of 50.2% (SD: 14.9) and 46.3% (SD: 16.2) when the mice received EPI at 40 and
300 mg/kg, respectively, compared to the untreated infected control group. In Table 1, all re-
sults are summarized.
Fig 1. Neutral and ionic forms of EPI (A). Potentiometric pKa determination (B). Illustration of the pKa values of EPI predicted using the ChemAxon method
(C). This graph shows the variation in the of distribution species vs pH values, and indicates that the ChemAxon predicted pKa values are respectively
pKa1 = 6.40 and pKa2 = 13.90 (C). DSC (D) and DSC-TGA (E) data illustrating the thermal degradation that occurs around 220°C in a single step.
doi:10.1371/journal.pntd.0003656.g001
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Effect of EPI on adult S.mansoni
The efficacy of EPI was tested against the adult parasite life stage in an experimental mammali-
an host. After 45 days of infection, male and female worms had matured and paired, and eggs
were found in the liver, intestine, and faeces. In mice infected by S.mansoni, there was a reduc-
tion in worm burden upon oral treatment by EPI, as shown in Table 2. After 45 days of infec-
tion, the treatments performed with EPI in doses of 40, 100 and 300 mg/kg reduced the worm
burden of the mice to 70.0% (P<0.001) (SD: 15.7), 39.0% (P<0.01) (SD: 14.1) and 46.7%
(P<0.001) (SD: 9.2) respectively.
Effect of EPI on egg elimination and liver and spleen weight
The effect of EPI on egg development stages (oogram pattern) and fecal egg burden at 45 days
post infection is shown in Table 3. In relation to the number of eggs excreted in the faeces, the
Table 1. Effects of EPI against juvenile S.mansoniBH strain (treated 21 days post infection).
Sample Dose Mean worm burden ± SEM (liver and porto-mesenteric) Reduction in total worm burden
Male Female Couples Total Worms
Control 0 (PBS only) 10.2±2.8 3.9±0.6 9.6±1.8 32.9±3.7 -
EPI 40 mg/kg 2.2±0.5* 2.4±0.6 5.9±0.7 16.4±1.7** 50.2%
EPI 300 mg/kg 6.8±1.4 0.9±0.3*** 5.0±1.0* 17.6±1.4** 46.3%
Values are presented as mean ± SEM. Number of animals/group = 8.
Asterisks indicate that difference compared to the control was significant with ***P<0.001, **P<0.01 and *P<0.05.
doi:10.1371/journal.pntd.0003656.t001
Table 2. Effects of EPI against adult S.mansoniBH strain (45 days post infection).
Sample Dose Mean worm burden ± SEM (liver and porto-mesenteric) Reduction in total worm burden
Male Female Couples Total Worms
Control 0 (PBS only) 12.9±1.1 9.9±1.2 13.7±0.9 50.2±2.4 -
EPI 40 mg/kg 2.6±0.6*** 2.2±0.7*** 5.3±0.9*** 15.2±2.5*** 70.0%
EPI 100 mg/kg 7.1±1.0** 6.8±1.3* 8.7±0.7** 31.4±2.7*** 39.0%
EPI 300 mg/kg 12.1±1.1 3.0±0.3*** 6.1±08*** 27.4±1.7*** 46.7%
Values are presented as mean± SEM. Number of animals/group = 10. Group treated with 100 mg /kg 3 animals died.
Asterisks indicate that difference compared to the control was significant with *** P<0.001, **P<0.01 and *P<0.05.
doi:10.1371/journal.pntd.0003656.t002
Table 3. Effect of treatment with EPI on oviposition by adults, 15 days post-treatment (45 days post infection).
Samples Dose (mg/kg) Reduction in number of eggs in faeces Percentage of eggs developmental stage
Immature Mature Dead
Control PBS - 79.0% 19.0% 2.0%
EPI 40 mg/kg 80.0%*** 24.0%*** 40.0% 36.0%***
EPI 100 mg/kg 45.7% 16.6%*** 59.4% 24.0%***
EPI 300 mg/kg 59.6%*** 56.8*** 31.2% 12.0%***
Number of animals/group = 10. Group treated with 100 mg /kg 3 animals died.
Asterisks indicate that difference compared to the control was significant with *** P<0.001
doi:10.1371/journal.pntd.0003656.t003
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results showed reductions of 80% (SD: 9.1), 45.7% (SD: 22) and 59.6% (SD: 35.2) in response to
treatments with 40, 100 and 300 mg/kg of EPI, respectively. It can be seen that in the groups
treated by EPI at 40, 100 and 300 mg/kg, the percentage of immature eggs was significantly re-
duced to 24% (SD: 13.6), 16.6% (SD: 11.1) and 56.8% (SD: 13.7) of the total number of eggs,
compared with infected untreated controls, in which 79% (SD: 6.1) of the eggs were immature.
The oogram also showed significant increase in percentage of dead eggs in the mice treated
with EPI (36% (SD: 9.9), 24% (SD: 5.6) and 12% (SD: 6.1) respectively) compared with the con-
trol group (2%) (SD: 1.2).
In addition, treatment with EPI 40 mg/kg decreases liver and spleen pathology. A significant
reduction in the weight of liver (P<0.01) and spleen (P<0.01) of the group treated with EPI
compared to the infected untreated control was demonstrated (Table 3). Treatment with EPI
100 mg/kg was significantly reduced only in the liver (P<0.05). On the other hand, mice treat-
ed with EPI 300 mg/kg did not see any reduction in the weight of these organs (Table 4). In
short, EPI significantly decreases S.mansoni egg and worm burdens, as well
as hepatosplenomegaly.
Effect of EPI on the tegumental changes
The alterations of the tegument on the S.mansoni surface treated with EPI were analyzed by
scanning electron microscopy (SEM). In control (untreated) parasites the tubercles and spines
appeared intact, and at high magnification, the surface showed spiny tubercles and ridges be-
tween the tubercles which have a pitted appearance and bear sensory papillae (Fig. 2A and B).
The tegument was dramatically damaged following the treatment with EPI, spines completely
absent and tubercules badly damaged (Fig. 2C and D). The changes included the swelling of tu-
bercles, and the loss of spines on tubercles, and sloughing and erosion. All worms examined
showed shrinking with furrowing, extensive sloughing around the tubercles on the tegument
exposing subtegumental tissues (Fig. 2C). In comparison with untreated worms, the overall
structure of the worms treated by EPI showed far greater changes, with tegumental ridges no
longer visible at low resolution (Fig. 2D), and far fewer intact tubercles visible, and no spines
seen at all. It is also worth noting that control worms and EPI—treated worms were
obtained whole.
Hepatic histopathology and granuloma measurement
Whereas the dose of 40 mg / kg led to a greater reduction in parasite burden, we evaluated
the presence of granulomas in the liver of mice treated with this dose. A detailed study of his-
tological sections of liver from the same area from BALB/c mice infected with S.mansoni
and treated with dose of 40 mg/kg of EPI (Fig. 3A and B) and the untreated control (Fig. 3C
and D) allowed the identification of granulomas at various stages of evolution containing
Table 4. Effect of treatment with EPI on relative organ weight.
Sample Relative liver weight Relative spleen weight
Control 1.88 ± 0.098 0.61 ± 0.034
EPI 40 mg/kg 1.60 ± 0.03** 0.45 ± 0.03**
EPI 100 mg/kg 2.00 ± 0.06* 0.61 ± 0.01
EPI300 mg/kg 1.78 ± 0.05 0.54±0.02
Asterisks indicate that difference compared to the control was significant with **P<0.01 and *P<0.05.
doi:10.1371/journal.pntd.0003656.t004
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infiltrate inflammatory compound of eosinophils, macrophages, neutrophils around the
egg and more externally lymphocytes and fibroblasts. Based on the classification of Lenzi
et al., 1998 [35], we identified in the liver histological sections granulomas containing some
disorganized inflammatory infiltrate around the egg (pre-granulomatous phase initial reac-
tion), excess diffuse inflammatory infiltrate (pre-granulomatous phase exudate), inflammato-
ry infiltrating loose and necrotic cells around the egg (necrotic-exudative phase), initial
deposition of collagen fibers by fibroblasts lining the inflammatory cells (productive phase)
and thick bands of collagen fibers surrounding the eggs and their remains (phase healing by
fibrosis).
Fig 2. Scanning electronmicroscopy of the mid-body dorsal region of male S.mansoniworms recovered from amouse 45 days post-infection by
portal perfusion. A and B: Untreated (control) worms. C and D: worms from rodents treated with 40 mg/kg EPI. Scales bars in A and C show 5 μm, and in B
and D show 10 μm. (A): dorsal tegumental surface showing tubercles (T), apical spines (s) and parallel wrinkles (w). (B) Lower magnification of (A) showing
the same features regularly appearing across surface. (C) and (D): SEM of male worm after treatment with EPI: Tubercles (T) and the lateral tegument
disintegrate (di) resulting in disappearance of the knobs, spines and many of the parallel-arranged wrinkles. Dorsal tegumental surface shows swelling (sw),
and erosion (er) of the surface with the exposure of subtegumental tissue. Overall appearance quite different to that of the control worms, due to erosion of
tubercules and loss of all apical spines.
doi:10.1371/journal.pntd.0003656.g002
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Decreases in the granuloma sizes were observed in the livers of the group treated with EPI.
Upon analysis of the images, it could be seen that the average diameter of the hepatic granulo-
mas was significantly smaller (P<0.01) in the group treated with EPI, in comparison to the un-
treated infected control group (Table 5). Furthermore, most of the S.mansoni eggs from the
animals treated with EPI showed of severe degeneration (71% versus 50% for the controls).
Fig 3. Photomicrographs of hepatic granulomas of mice liver 45 days post infection. A and B: Liver of treated infected animals (40 mg/kg). Note the
necrotic-exudative phase with loose inflammatory infiltrate (macrophages, neutrophils and eosinophils) and areas with necrotic cells around the egg. C and
D: Liver of untreated infected animals, the granulomas were found in the periportal area. Different stages of evolution of the granuloma, including
granulomatous pre-exudative, necrotic-exudative, productive and healing by fibrosis were observed. Arrows indicate the presence of inflammatory cells.
doi:10.1371/journal.pntd.0003656.g003
Table 5. Granuloma diameter (μm) in the liver of the mice from treated and untreated adult worm-in-
fected groups 45 day post infection.
Sample Granuloma diameter average (μm) ± SEM Number of granulomas
Control infected Untreated 243.5 ± 3.23 68
EPI 40 mg/kg 194.0 ± 6.95** 30
Difference was significant ** P<0.01.
doi:10.1371/journal.pntd.0003656.t005
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Toxicity and histopathological studies
Toxicity and histopathology studies were carried out to assess the toxicological profile of EPI in
vivo. The concentrations tested were considerably higher than the therapeutic doses used to
measure effects on S.mansoni, since the toxicity of PZQ is low, with a DL50 around 2,400 mg/kg
[36]. Intraperitoneal injection of EPI at a concentration equal to or higher than 530 mg/kg
caused visible clinical changes such as tachycardia, tachypnea, ataxia and prostration. After a
period ranging from 15 minutes to 6 hours, these changes were spontaneously reversed, eventu-
ally becoming imperceptible to observation, in a dose dependent way. The maximum concen-
tration of 8,000 mg/kg killed 50% of animals with 18 hours of intraperitoneal injection of
the drug.
Fig. 4 shows images illustrating the histology of the liver (Fig. 4A, B and C), spleen (Fig. 4D,
E, F), lung (Fig. 4G, H, I), kidney (Fig. 4J, K, L), and brain (Fig. 4M, N, O) treated with 0.0 (first
column), 530 (second column) or 8000 (third column) mg/kg of EPI. The histopathological
analysis showed that the animals treated with the highest concentration (8,000 mg/kg) showed
generalized congestion and edema in the histological sections of lung, spleen, kidney, and
brain; depression in the red pulp and uncountable cells undergoing apoptosis in the spleen, as
well damage in the endothelium of the vessels in the liver were also observed (Fig. 4F). Other
effects observed following 8,000 mg/kg injection included intra-alveolar hemorrhage and fibrin
deposition in the lung (Fig. 4I) and focal hydropic degeneration of the kidney (Fig. 4L); no
morphological changes were observed in the parenchyma of the liver (Fig. 4C). Animals treated
with 530 mg/kg EPI showed focal depression of the red pulp (Fig. 4E) after seven days of intra-
peritoneal injection of the drug, while the other organs presented no morphological changes
(Fig. 4B, H, K, N). The control group showed normal morphology in all organs analyzed
(Fig. 4A, D, G, J, M).
Discussion
The widespread use of PZQ for treatment and control schistosomiasis may select drug-resistant
parasites [37]. In countries like Egypt, an increasing number of patients have displayed resis-
tance to treatment with PZQ, apparently due in some cases to resistance inherent in particular
strains, and in other cases to an immune response from the infected host, which reduces che-
motherapy effectiveness [38]. Therefore, the discovery of new antiparasitic agents to treat
schistosomiasis is an important avenue of research.
Plant compounds have attracted the attention of many researchers over the years for the de-
velopment of new drugs, due of the variety of their chemical structures and their broad range
of biological activities. Discovery of untapped natural sources that can be used in treatment of
schistosomiasis remains a major challenge in the era of combinatorial chemistry and genomics
[28].
We have evaluated the activity of a single dose of EPI against the laboratory model S.man-
soni in vivo, firstly to determine the acute toxicity (DL50) and also to determine the effect of dif-
ferent concentrations of EPI (40, 100 and 300 mg/kg) on S.mansoni infected-mice.
Our results for the acute toxicity showed that intraperitoneal injection of EPI at a concentra-
tion equal to or higher than 530 mg/kg caused visible clinical changes such as tachycardia,
tachypnea, ataxia and prostration, which were spontaneously reversed after 6 hours.
The treatment of S.mansoni infected-mice caused significant reductions in worm load, fae-
ces egg load, and the frequency of egg developmental stages and reductions in hepatospleno-
megaly. The effect on worm burden with single doses of 40 and 100 mg/kg of EPI showed there
was no significant difference in susceptibility between males and females. However treatment
with 300 mg/kg of EPI showed greater sensitivity by the female worms. Some susceptibility
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Fig 4. Histopathological study of organs sections of different groups of mice.Comparison between the
histology of: liver (A,B,C), spleen (D,E,F), lung (G,H,I), kidney (J,K,L), and brain (M,N,O) obtained from Swiss
mice (n = 4) treated with 0.0 (first column), 530 (second column) or 8000 (third column) mg/kg of EPI. The first
and the second column refer to mice killed 7 days after assay and the third one represent organs from
animals that died due to the administration of higher concentration of the drug. Light microscopy evaluation of
these organs showed severe morphological changes in the spleen, lung, kidney and brain, but not in the
parenchyma of liver in the animals treated with 8000 mg/kg of EPI. Focal alterations in the red pulp were
observed in the spleen of animals treated with 530 mg/kg of the drug. Control group presented no
morphological changes in the organs.
doi:10.1371/journal.pntd.0003656.g004
Anthelmintic Activity In Vivo of Epiisopiloturine against S. mansoni
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003656 March 27, 2015 12 / 18
differences related to dose are described in the literature. For example, some studies [38–41]
described that subcurative doses of PZQ act in the same proportion on males and females, with
no significant differences in the therapeutic sensitivity between the genders. But Delgado et al.
[25] also observed that the in vivo concentration of 250 mg/kg of PZQ acts preferentially on fe-
males of this parasite. Other works with antischistosomal drugs have also shown female worms
with greater susceptibility than male worms [28, 31, 42, 43].
The in vivo treatments against immature worms of S.mansonimodify the proportion be-
tween male and female parasites. The treatments with the 40 and 300 mg/kg doses showed a
moderate worm burden reduction, which did not significantly increase at the higher concentra-
tions. (50.2% with SD: 14.9 and 46.3% with SD: 16.2, respectively). Utzinger et al. [44] observed
that juvenile worms were not susceptible to PZQ. Probably the effect of EPI against juvenile
worms can be an advantage in relation to PZQ.
At the end of the treatment, the weight of the liver and spleen of infected mice treated with
40 mg/kg of EPI were lower than of those from control infected mice. The anti-inflammatory
properties of EPI may have helped in this effect. But, this reduction did not happen at doses of
100 and 300 mg/kg. Given the fact that S.mansoni leads to severe granulomatous inflammatory
reactions in the liver, a compound with anti-inflammatory properties might be of great interest
in the enhancement of the anti-inflammatory barrier. The immediate consequence was a re-
duction of the number and the size of granulomas in the liver and then a reduction of hepatos-
plenomegaly. Treatment with doses of 100 and 300 mg/kg did not show the same result
compared with 40 mg/kg. This could indicate that the greater doses overcome the anti-inflam-
matory effect seen at lower doses, possibly due to a change in the partition of the drug when
doses are increased [45].
Interestingly, looking at the total worm burden data (Table 1), greater decreases in worm
burden were obtained at 40 mg/kg compared with either 100 or 300 mg/kg. The differences in
the worm burdens between the two upper concentrations were not significant, although the de-
crease in both cases, although less than that seen with a dose of 40 mg/kg, was significant com-
pared to the control. In addition, considering Table 2, we see that a similar dose dependence
can be observed in the effect on egg laying. 100 and 300 mg/kg doses both lead to significant re-
ductions in oviposition, but a greater effect was observed following the smaller dose of 40 mg/
kg. Although inverse dose-response relationships are not unknown, they are unusual. In this
case, the reason for this could be related to the administration method. The higher doses could
lead to precipitation in the gut, leading to a failure to absorb. A very important future goal is to
determine the pharmacokinetics of this drug in the model, to help explain these data. Further
future experiments could also probe even smaller doses.
Although we were unable to observe significant toxicity at these treatment conditions, 3 ani-
mals did die after treatment with 100 mg/kg. It seems from this work that treatment with EPI
at concentrations above 40 mg/kg do not offer any advantages in this model.
We carried out a comparison of the numbers of immature, mature and dead eggs present in
the intestinal fragments of hosts—treated (45 days post-infection) and untreated. Our results
demonstrated a significant decrease in the percentage of immature eggs in the intestinal tissue
of the treated animals at all doses when compared to the untreated infected control groups.
The decrease in the percentage of immature eggs in treated mice probably results from a de-
crease of worm burden and an effect on the reproductive fitness of S.mansoni. Probably the in-
crease in the mature eggs compared to immature ones, happened as result of anterior
oviposition. The results presented here concerning the reduction of eggs match those observed
in other studies of effects of different compounds on S.mansoni [13, 46]. The reduction in ovi-
position is rather important for therapeutic use since the egg is responsible for transmitting the
parasite and maintenance of its biological cycle. Furthermore, pathology associated with
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human schistosomiasis is thought to be due to the large number of eggs that become trapped in
host tissues [47].
In addition, we evaluated the effect of EPI on egg load. The alkaloid significantly reduced
(P<0.001) the number of eggs per gram of faeces compared to control. This remarkable reduc-
tion of fecal egg count could be related to decrease parasite load. Similar results were obtained
by Moraes et al., 2014 [13] in studies with phytol.
Since the dose of 40 mg/kg led to a greater reduction in parasite burden, we evaluated the
presence of granulomas in the liver of mice treated with this dose. The livers of EPI treated
mice showed reduced granuloma diameters and a preserved typical lobular architecture. Eosin-
ophils cells are known to play a major role in ovum destruction both in vitro [48] and in vivo
[49] and amelioration of hepatic pathology and the presence of small granulomas with pre-
dominant eosinophils as a result of accelerated egg destruction upon repeated administration
of soluble antigens of the parasite eggs (SEA) have been reported [50]. Therefore, there is the
possibility that the increase in the number of degenerated eggs, as well as the decrease in the di-
ameter of granulomas after treatment with EPI has occurred due to immunological interven-
tions and immunomodulating actions. A similar effect was shown by Miranda et al., 2013 [51]
in studies with the alkaloidic extract of Solanum lycocarpum fruits. This extract showed immu-
nomodulatory effect on mice infected with S.mansoni.
The tegument is a prime target for drug studies, alterations in the surface topography of
schistosome worms has been studied by several investigators [52–54]. The EPI doses tested ex-
hibited a severe effect on the tegument of adult S.mansoni comprising of swelling of the tuber-
cles and ridges, followed by loss of spines. Subsequently, the tubercles and ridges were broken
and began to erode, leading to the formation of lesions. Eventually this resulted in sloughing of
the tegument over large areas of the body surface. We speculate that the morphological changes
found in the tegument can be a mechanism by which EPI leads to death of the worms. The
damage to the tegument along the worm's body could have destroyed the defense of the
worms, enabling subsequent attack by the immune system. The mechanisms involved in schis-
tosomes death may be dependent on host antibodies or direct effect, [13]. Based on the premise
that thioredoxin glutathione reductase (TGR) is an enzyme essential for the survival of the par-
asite S.mansoni [55], we did docking EPI with the TGR, but the EPI did not bind the enzyme
and thus, we suppose that this is not the target. Thus, further studies are needed to elucidate
the multiple mechanisms of action of EPI. This will be the subject of future study.
Toxicological evaluation of new drugs is one of the decisive steps of drug development.
Filho et al., 2002 [56] evaluated three oxamniquine derivatives as novel schistosomicide agents
when administered to mice. Oxamniquine has a DL50 value of 1,300 mg/kg, and the three new
derivative compounds had even higher toxicities, with values of DL50 less than 1,200 mg/kg.
PZQ, when administered to mice, has a DL50 around 2,400 mg/kg [35]. In our case, EPI was
shown to have a far greater DL50 (8,000 mg/kg) and the mice were seen to have a high resis-
tance to the toxic effects of EPI. The most dramatic histopathological alterations caused by
EPI, such as generalized congestion and edema in the histological sections of lung, spleen, kid-
ney, and brain, depression in the red pulp and the uncountable cells undergoing apoptosis in
the spleen, intra-alveolar hemorrhage and fibrin deposition in the lung, focal hydropic degen-
eration of the kidney and damage in the endothelium of the vessels in the liver may be respon-
sible for the toxicity at the highest concentration of 8,000 mg/kg. Below 530 mg/kg EPI caused
no toxicity and caused no visible clinical changes at all, which potentially could be a consider-
able advantage to its clinical use. Although at this early stage, we have not carried out experi-
mental tests of genotoxicity, we have carried out a theoretical prediction exercise. Osiris
Property Explorer [57] is a tool widely used to evaluate the drug-score of potential compounds
to meet potential candidate drug requirements. The toxicity risk assessment is predicted
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through a process based on comparison with a precomputed set of structural fragments which
come from the toxic group from the RTECS database (Registry of Toxic Effects of Chemical
Substances), maintained by US National Institute for Occupational Safety and Health
(NIOSH). Toxicity data scores generated include primary irritation; mutagenic effects; repro-
ductive and tumorigenic effects; acute toxicity and multiple dose toxicity. When EPI and its
stereoisomers were evaluated through this tool (http://www.organic-chemistry.org/prog/peo/
accessed on February 01th 2015), no toxicity risks were found. Similarly, we also compared the
structural features of EPI to a published of Pan Assay INterference compounds or PAINs
groups, promiscuous, and assay-interfering activities, and found no match [58]. Nevertheless,
such prediction tools are no substitute for experimental testing and, considerable further test-
ing is required in the future regarding the safety of this new alkaloid, specifically genotoxicity
and reproductive toxicity data will be needed.
The results of pKa shown that the EPI can be used safely at physiological pH without any
loss of activity or appearance of toxic derivatives.
The results of in vitro assays with many drugs do not correspond to what is observed in
vivo. In fact, what works well in vitro may not work in vivo and vice versa, as shown by Katz
et al., 2013 [59]. Our article clearly shows—in S.mansoni, considerable differences in a drug’s
efficacy in vitro and in vivo. EPI is not very potent in vitro—this is a fact. But the response that
we measured in vivo (40 mg/kg) was reasonable (n = 10), this number of animals is appropriate
to the experiment according to the literature.
An important practical aspect to be considered is that EPI can be extracted and purified
from the waste of the production of pilocarpine from jaborandi leaves (Pilocarpus microphy-
lus), so that it is expected that total production costs compared to other active pharmaceutical
ingredients would be very low.
Conclusions
In conclusion EPI significantly reduced parasite worm burden and the alkaloid showed no
measurable toxicity in the model tested, at concentrations superior to effective treatment con-
centrations. At this time, EPI is a promising candidate drug. More studies are needed to evalu-
ate the therapeutical effectiveness of EPI, and to evaluate the efficacy of this drug against
different stages of the life cycle as well as other species of Schistosoma. In the future, pharmaco-
kinetic studies to explore the fate of the drug in the body are required. Additionally, the de-
tailed mechanism of action of EPI in schistosomes remains to be investigated with other
preclinical tests.
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